Advertisement

PentaVision

Retinal Physician

Article | 2026 Retina World Congress

Peptide eye drop could offer a noninvasive alternative to injections for nAMD treatment 

Phase 1 data showed that investigational CG-P5 eye drop therapy reduced central retinal thickness. 

By: Matthew Solan, senior writer
Retinal Physician June 1, 2026

Peptide eye drop could offer a noninvasive alternative to injections for nAMD treatment

Overview

Phase 1 data presented at Retina World Congress 2026 indicates that CG-P5 eye drop therapy significantly reduces central retinal thickness in patients with neovascular age-related macular degeneration (nAMD).

Background

Neovascular age-related macular degeneration (nAMD) is a leading cause of vision loss in older adults, traditionally treated with intravitreal anti-VEGF injections. These injections, while effective, can be burdensome for patients due to the need for frequent administration. The development of noninvasive alternatives, such as topical therapies, could enhance patient compliance and comfort.

Data Highlights

ParameterCG-P5AfliberceptPlacebo
Central Subfield Thickness Reduction at Day 56Statistically significantComparableN/A
Intraretinal Fluid Clearance Rate at Day 5683%60%25%
Disease Activity Reduction by Day 8478%57%N/A

Key Findings

  • CG-P5 eye drops demonstrated a statistically significant reduction in central retinal thickness compared to placebo.
  • The magnitude of CST reduction with CG-P5 was comparable to that of aflibercept.
  • CG-P5 achieved an 83% intraretinal fluid clearance rate at day 56, outperforming both aflibercept and placebo.
  • Approximately 20% of patients reported mild, temporary eye irritation, which resolved quickly.
  • CG-P5 produced a 78% reduction in disease activity by day 84, compared to a 57% reduction in the aflibercept group.

Clinical Implications

Further studies are necessary to confirm the efficacy and durability of CG-P5 in larger patient populations.

Conclusion

Further validation in larger trials is needed for CG-P5 eye drop therapy.

Related Resources & Content

  1. Retinal Physician, April 2024 -- Improving Durability of Drugs in Wet AMD
  2. Optometric Management, October 2025 -- Dry Eye: Supporting Patients...
  3. The Ophthalmologist, May 2026 -- A Topical Route to Neuroprotection?
  4. Age-Related Macular Degeneration Preferred Practice Pattern® - Ophthalmology
  5. ClinicalTrials.gov -- Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration
  6. Retinal Physician — Tyrosine Kinase Inhibitors for Wet AMD and Diabetic Retinopathy
  7. Age-Related Macular Degeneration Preferred Practice Pattern® - Ophthalmology
  8. Efficacy, durability, and safety of intravitreal faricimab up to every 16 weeks for neovascular age-related macular degeneration (TENAYA and LUCERNE): two randomised, double-masked, phase 3, non-inferiority trials - PubMed
  9. Study Details | NCT06132035 | Study to Evaluate the Safety of CG-P5 Peptide Eye Drops in Patients Diagnosed With Age-related Wet Macular Degeneration | ClinicalTrials.gov